Roche has licensed an antibody-drug conjugate (ADC) designed to treat advanced small-cell lung cancer from China-based Innovent Biologics for $80 million up front and up to $1 billion in milestone ...
In separate DLL3 antibody-drug conjugate (ADC) deals, Roche licensed from Innovent Biologics and Ideaya reached for Hengrui.
Swiss pharmaceutical corporation Roche has acquired the antibody-drug conjugate (ADC) candidate from the Chinese biotech company Innovent Biologics for a total contract value of $1 billion ...
Roche's strategic changes in drug development and M&A activity may drive future growth, despite recent setbacks in clinical ...
Innovent inks exclusive global license agreement with Roche to advance the development of IBI3009, a novel DLL3 targeted ADC candidate: San Francisco, US Friday, January 3, 2025, ...
Global markets have recently shown mixed performances, with the S&P 500 and Nasdaq Composite both closing out a strong year despite some volatility and profit-taking towards year-end. In this ...
After inking a series of partnerships late last year, Lonza’s antibody-drug conjugate (ADC) specialist Synaffix is kicking ...
Innovent has submitted a second new drug application (NDA) to China's National Medical Products Administration (NMPA) seeking approval for Dovbleron as a treatment for ROS1-positive advanced NSCLC ...
China is adapting its Life Sciences policy to bolster innovation and data transparency. Big Pharma is taking note.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback